ライフサイエンスコーパス: ARNI

1 ARNI prescribing patterns in hospitalized patients with

2 nhibitor/angiotensin receptor blocker 31.6%, ARNI 19.0%) and for ACE inhibitor/angiotensin receptor b

3 atio 0.44, 95% credible interval 0.26-0.66); ARNI+BB+MRA was associated with the greatest reduction i

4 , GLP-1a (glucagon-like-peptide 1 agonists), ARNI (angiotensin receptor-neprilysin inhibitors), and f

5 antial and support the combination use of an ARNI, beta blocker, MRA, and SGLT2 inhibitor as a new th

6 cluded in analysis, 12.6% were prescribed an ARNI at discharge.

7 , 72 [95% CI, 58-89]; P<0.001) and taking an ARNI before hospitalization (OR 9 [95% CI, 7-13]; P<0.00

8 sed on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested treatment-by-subgr

9 implantation (stage D; primary analysis) and ARNI therapy initiation (stage C; matched reference).

10 et doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectively.

11 that treatment with ACEI, ARB, BB, MRA, and ARNI and their combinations were better than the treatme

12 HFmrEF/HFpEF, or combined SGLT2i, nsMRA and ARNI therapies in a 65-year-old patient with an LVEF <60

13 81), while combined use of SGLT2i, nsMRA and ARNI therapies was estimated to reduce risk by 39% in pa

14 n medical therapy with SGLT2i and nsMRA (and ARNI in selected individuals) are projected to be substa

15 inhibitor/angiotensin receptor blocker (ARB)/ARNI contraindication was associated with lower likeliho

16 eously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA.

17 The 4 new therapeutic classes discussed are ARNIs, SGLT2 (sodium-glucose cotransporter 2) inhibitors

18 r ACE inhibitor/angiotensin receptor blocker/ARNI, decreased over time.

19 nhibitor/ARB (angiotensin receptor blockers)/ARNIs (angiotensin receptor-neprilysin inhibitors; 0.54

20 of quadruple therapy and regimens excluding ARNI or SGLT2i.

21 r beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresponding proportions with discontinuation or

22 $84-$100), including $47 (IQR: $40-$47) for ARNI and $45 (IQR: $40-$47) for SGLT2i.

23 nhibitor or angiotensin receptor blocker for ARNI.

24 96 (84%) were projected to be candidates for ARNI therapy.

25 Eligibility criteria for ARNI therapy, population-based estimates of patients wit

26 While 68.1% were eligible for ARNI, only 6.0% received them, reaching 17.2% by 2020.

27 t sharing was required by 99.1% of plans for ARNI and 98.5% for at least 1 SGLT2i.

28 discounts off the increasing list prices for ARNI and SGLT2is.

29 l differences, particularly for hydralazine, ARNI, devices, and cardiac rehabilitation.

30 Potential targets for improving ARNI prescription rates include initiating ARNIs during

31 ing opportunity for continued improvement in ARNI prescription.

32 Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among patients with heart failu

33 Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to p

34 Angiotensin receptor-neprilysin inhibitor (ARNI) prescription in the United States remains suboptim

35 e angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan has been shown to improve out

36 , angiotensin receptor neprilysin inhibitor (ARNI) treatment, New York Heart Association (NYHA) funct

37 r angiotensin receptor-neprilysin inhibitor (ARNI) use decreased over time, and hydralazine/nitrate u

38 , angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor anta

39 s angiotensin receptor neprilysin inhibitor (ARNI), in patients with this disorder.

40 n angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF

41 , angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonists, and sodiu

42 angiotensin receptor-neprilysin inhibitors (ARNI), have not been studied in a head-to-head fashion.

43 nsin receptor blocker neprilysin inhibitors (ARNIs) have been associated with improvements in hospita

44 angiotensin receptor-neprilysin inhibitors (ARNIs); (2) beta-blockers; (3) platelet adenosine diphos

45 angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhib

46 g ARNI prescription rates include initiating ARNIs during hospitalization and aggressively addressing

47 The combination of ARNI+BB+MRA resulted in the greatest mortality reduction

48 f worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with AC

49 PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With AC

50 (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with AC

51 In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with AC

52 sis of PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with AR

53 : The Personalized Prospective Comparison of ARNI [angiotensin receptor/neprilysin inhibitor] With AR

54 es in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

55 PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

56 PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

57 (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality a

58 n the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality a

59 n the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality a

60 n the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

61 PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

62 action (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality a

63 In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

64 PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality a

65 gated these in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

66 The PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

67 n the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

68 a subpopulation of Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality a

69 m the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality a

70 PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality a

71 HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality a

72 The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global

73 (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompens

74 40% (PARAGLIDE-HF [Prospective comparison of ARNI with ARB Given following stabiLization In DEcompens

75 PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompens

76 in the PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Eject

77 While the Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Eject

78 The PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Eject

79 (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Eject

80 PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Eject

81 re measured in the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preser

82 The dominant determinants of ARNI prescription were ARNI use while inpatient (odds ra

83 uld be gained from optimal implementation of ARNI therapy at the population level have not been quant

84 Optimal implementation of ARNI therapy was empirically estimated to prevent 28484

85 ly be prevented by optimal implementation of ARNI therapy.

86 tion was associated with lower likelihood of ARNI prescription at discharge (OR, 0.11 [95% CI, 0.10-0

87 factors associated with lower likelihood of ARNI prescription included having no insurance (OR, 0.60

88 5-fold (95% CI, 8.79-9.52) increased odds of ARNI prescription at discharge, and a 0.46 (95% CI, 0.45

89 Overall prescription of ARNI at discharge was 55.4% in eligible patients at the

90 The rate of ARNI prescription is increasing with time, but the dispa

91 g approval of sacubitril-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge inc

92 Rates of ARNI prescribed at discharge increased from 1.1% (27 of

93 oeconomic factors contribute to low rates of ARNI prescription at hospital discharge.

94 Rates of ARNI, ACEI, and ARB prescription at discharge were evalu

95 Rates of ARNI, angiotensin converting enzyme inhibitor (ACEI), an

96 deaths prevented or postponed as a result of ARNI were estimated along with multiple-way sensitivity

97 evaluate the impact of publication dates on ARNI prescription rates.

98 in cardiac function following initiation on ARNI or left ventricular assist device implantation.

99 t (g<0.10) to stage C HF after initiation on ARNI therapy.

100 Only ARNI required prior authorization (24.3% of plans), and

101 il-valsartan, rates of ARNI or ACEI, ARB, or ARNI prescription at discharge increased, and rates of A

102 over the same period, whereas ACEI, ARB, or ARNI prescription increased from 71.1% (2639 of 3713) to

103 0.27 [95% CI, 0.27-0.28] for ACEIs, ARBs, or ARNIs; 0.24 [0.24-0.25] for beta-blockers; 0.20 [0.19-0.

104 The PARADISE-MI (Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority

105 The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority

106 rolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in

107 alysis of the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in

108 ccount for background therapy suggested that ARNI monotherapy is more efficacious than ACEI or ARB mo

109 e disease-modifying pharmacological therapy (ARNI, beta blocker, MRA, and SGLT2 inhibitor) versus con

110 iples herein could be used with reference to ARNI, finerenone, or any other health product.

111 inant determinants of ARNI prescription were ARNI use while inpatient (odds ratio [OR], 72 [95% CI, 5

112 al and socioeconomic factors associated with ARNI prescription at hospital discharge.

113 ith reduced ejection fraction treatment with ARNI (angiotensin receptor/neprilysin inhibitor) therapy

114 substitution of ACE inhibitors or ARBs with ARNIs in appropriate patients.